global aggregate spend and … aggregate spend and transparency reporting ... which biz unit is...
TRANSCRIPT
www.pwc.com
Global Aggregate Spend and Transparency Reporting
May 15 2012May 15, 2012
The Global Movement to TransparencyThe Global Movement to Transparency
• We have witnessed significant parallels between the U.S. and rest of world g prelated to the development around, and enforcement of, laws, regulations and industry guidances
Industry Codes of Conduct (PhRMA Code IFPMA Code) Industry Codes of Conduct (PhRMA Code IFPMA Code)
Payments to Healthcare Professionals (Federal False Claims Act FCPA)
Data Privacy (HIPAA EU Data Protection)Data Privacy (HIPAA EU Data Protection)
State Laws Local Country Laws
• Now global entities are focused on Transparency, specifically as it relates to how, and how much, companies are spending money on health care professionals, organizations and other related entities
Slide 2
Evolving Global Regulatory LandscapeEvolving Global Regulatory Landscape
Healthcare Compliance Legislation and Regulatory Guidelines p g g yTimeline
Slide 3
Evolving Global Regulatory LandscapeEvolving Global Regulatory Landscape
Scrutiny of pharmaceutical, medical device, and biotech business y ppractices has spread beyond the US borders
Increasingly complex and changing global regulatory and public landscapeIncreasingly complex and changing global regulatory and public landscape• At least 8 countries have existing disparate legislation setting compliance
requirements, limits on industry engagement, and payments to customers and/or requiring the disclosure of these payments & costsand/or requiring the disclosure of these payments & costs
• Some countries have even mandated pre-approval prior to engaging a covered recipientM i ill b i di i d i• More countries will be passing distinct aggregate spend requirements
• Codes of Conduct and industry trade group regulations can also impart pre-approval and disclosure requirements
Slide 4
Evolving Global Regulatory LandscapeEvolving Global Regulatory Landscape
New legislations and Industry Codes of Conduct that govern the way g y g ythe pharmaceutical industry interacts with Covered Recipients are being introduced around the globe to varying degrees
Type of Requirement Implication
Pre-Approval Prior to contracting with a Covered Recipient, pre-approval needs to be sought from a designated agency
Disclosure of the amount and/or frequency and/or source of transfers of value to Covered Recipients
Disclosure
transfers of value to Covered RecipientsAggregate Disclosure:
Requires a company to di l th t t l b
Individual-Level Disclosure:
Required the disclosure of th t d i i t
Cross-BorderDisclosure:
Disclosure of transfers of l t C dDisclosure disclose the total number
of Covered Recipients engaged and total value of transfers made in any given year, without indi id al le el
the amount and recipient of each individual transferof value made in a given year.
value to Covered Recipients even if they are incurred outside of home country borders
individual level disclosures.
Slide 5
Evolving Global Regulatory LandscapeEvolving Global Regulatory LandscapeContinued Focus on Transparency – Enacted/Pending Global Legislation
Countries with Existing Relevant Legislation
Countries with LegislationCountries with Legislation requiring Covered Recipient Disclosure and/or Pre-Approval
**”Relevant” legislation encompasses all legislation that requires pharmaceutical companies to disclose payments made to HCPs (including tax legislation)Slide 6
Evolving Global Regulatory LandscapeEvolving Global Regulatory LandscapeContinued Focus on Transparency – Industry Trade Group Regulations
Countries with Industry Trade Group Regulations
Countries with Industry TradeCountries with Industry Trade Group Regulations requiring Covered Recipient Disclosure and/or Pre-Approval
Slide 7
Evolving Global Regulatory LandscapeEvolving Global Regulatory LandscapeCode or
LegislationExisting Upcoming Pending Cross-
BorderDisclosure Timeline
France Sunshine ActCSP, DOMS
• Data Capture: January 2012• Reporting: August, 2012; every 6 months
Spain Tax Legislation (RD 1065, ’07)
• Individual payments must be reported to local tax authorities monthly• Summary declarations (total amount spend/any withholdings) reportedannually
India Tax Legislation • Currently capturing and reporting for tax purposes (annually)
Korea KRPIA
• Data Capture: Within 1 month of event• Reporting: Published by the KRPIA; for sponsorship payments,published the preceding quarter every January, April, July, andOctober
Australia Medicines Australia
• Data Capture: Currently capturing for spend at Educational Events• Reporting: Currently every 6 months
GreeceNational Organization of Medicines
• Since January 1, 2010, payments to Covered Recipients (domestically orcross border) must be submitted to the National Organization of Medicines
United States Sunshine Act
• Data Capture: TBD in 2012• Reporting: March 31, 2013; Yearly thereafter
United Kingdom
ABPI 2011 Code of C d t
• Data Capture: 2012 for donations and sponsorships and individualfee-for service, May 1, 2011 for all projects with patient groups (over250 pounds)R ti Withi 3 th f th d f th ’ fi i lg Conduct • Reporting: Within 3 months of the end of the company’s financial year;Yearly thereafter
Japan JPMA • Data Capture: FY2012• Reporting: FY2013; Yearly thereafter
Thailand Act of Public H lth
• Will be required to report payments to individual Covered RecipientsllThailand Health annually.
Nether-lands NEFARMA
• Payments to Covered Recipients/HCOs beyond 500 EUR per year must bepublished within 3 months after the year the financial relation becameeffective
Slide 8
What does this mean for industry?What does this mean for industry?
Scenarios to Consider
• Cross-border contracting of covered recipient
• Covered recipient used for research and commercial activities
• Covered recipient contracted in several countries
Slide 9
Scenario #1 Covered Recipient Contracted CrossScenario #1 – Covered Recipient Contracted Cross-Border
Who should manage theWhich Biz unit is Should each Biz Unit manage the
process associated with the PoTV for
an HCP?
Which Biz unit is responsible for
reporting the PoTV?
have a MDM for covered recipient
validation?
HCP licensed i GBin GB
1. Promotional Event in France
How should Biz
Event in France
How should Biz Units share PoTV information with Source Biz Unit?
How will the PoTV be captured and
reported?Slide 10
Scenario #2 HCP used for clinical and marketingScenario #2 – HCP used for clinical and marketing
Who should manage the Which Biz Unit is Should each Biz Unit
h MDM fgprocess associated with the PoTV for
an HCP?
c U t sresponsible for
reporting the PoTV?
have an MDM for covered recipient
validation?
HCP licensed in Francein France
2. Advisory Board in France
1. Research in S i f B d XBoard in France
for Brand X
How should Biz Unit share PoTV How will the PoTV
be captured and
Should we enable Global visibility into the engagement of
Spain for Brand X
information with Source Biz Unit
be captured and reported?
g gthe same HCP
across all of the Biz Units?
Slide 11
Scenario #3 HCP is Engaged by Multiple Biz Scenario #3 – HCP is Engaged by Multiple Biz Units to perform similar activities
Which Bi UnitWhich Biz Unit determines the Fair
Market Value?
Which Biz Unit is responsible for
reporting the PoTV?
How will the PoTV be captured and
reported?reporting the PoTV? reported?
HCP licensed in GB
How do you ensure the correct data is
collected?Slide 12
The Vision: End to end Global HCP spend The Vision: End-to-end Global HCP spend management
Companies are starting to take a complete HCP Spend Management approach from the initiation of an activity and budget planning through reporting to enable consistency and compliance through the entirety of reporting to enable consistency and compliance through the entirety of the business process
Activity and Budget
PlanningApproval Activity
Execution Tracking Reporting
As-is Reporting
Complete Tracking
F ll S d M tFull Spend Management
Slide 13
Aggregate Spend Solution ComponentsAggregate Spend Solution ComponentsThe following areas represent the solution components that need to be addressed as part of the Aggregate Spend future state design
Compliance
Reporting
Governance
Master Data Management
Reporting
Data Sources and Supplement/Remediate Data
Slide 14
Data Sources and Supplement / Remediate DataData Sources and Supplement / Remediate DataData sources must be addressed through modification, supplementation of transactional data, and/or training to address data capture gaps
• Global Inventory
• Documented Legal Interpretation
• Common Definitions Framework
• Data Capture Requirements
• Evaluation of Current Data Capture Systems
• Capture Interaction Details
Governance
Compliance• Capture Interaction Details
• Third-Party Data Entry
• Add Missing Data
Master Data Management
Reporting
Add Missing Data
• Remediate Data Gaps
Data Sources and Supplement/Remediate Data
Slide 15
Master Data ManagementMaster Data ManagementMaster data initiatives can reduce data remediation needs
• HCP & HCI Profiles & Unique IDs
• Align Transactions to Unique HCPs and HCOs
• International Customer Masters
• Identify Global KOLs
• Acquire Unique IDs and Tie to Master Data List
Governance
Compliance
Master Data Management
Reporting
Data Sources and Supplement/Remediate Data
Slide 16
ReportingReportingA reporting solution will act as the central repository for data and must be considered as part of the overall picture
• Consolidate Transactions
• Apply Business Rules
• Generate Spend Disclosure Reports
• Generate Additional Reports and Analysis
• Off-the-Shelf Solution vs. Outsourced
• Data Privacy and Protection• Data Privacy and Protection
Governance
Compliance
Master Data Management
Reporting
Data Sources and Supplement/Remediate Data
Slide 17
GovernanceGovernanceNew Processes, Standards, and Roles to Support Change
• Ownership and Accountability
• Organizational Support
• Data Standards
• Center of Excellence (COE)
• Risk and Regulatory
Governance
Compliance
Master Data Management
Reporting
Data Sources and Supplement/Remediate Data
Slide 18
GovernanceGovernance• Scope identification • Modifications to front-end systems• Data standards/system interfaces
D lid i d h dli
Source System Data
Gathering
Aggregate Spend
• Data validation and error handling
• Central data repository• Third-Party vendor portals• Master Data alignment
• Customer communication• Customer inquiries• Dispute processing
Gathering
Customer Inquiries
Data Aggregation & ReconciliationAggregate Spend
Support Framework
g• Validation of completeness
and accuracy• Corrections and reporting• Maintenance of web
reporting
Reconciliation
• Establish BI/Reporting framework• Apply business rules• Generate regulatory reports• Generate additional analysis
• Review and sub-certifications• Report modifications• Trending and outliers• Overall certification and submission• Validation through audit
Generating Reports & Insights
Certification &
Submission
Aggregate Spend Governance
Communication & Change Managementg g
Monitoring
Auditing
Slide 19
ComplianceComplianceEstablishing a Compliance Program allows manufacturers to meet state, federal, and international requirements and implement a robust Aggregate Spend SolutionSpend Solution
• Code of Conduct• Code of Conduct
• Common Definitions Framework
• Policies and ProceduresPolicies and Procedures
• Prohibited Interactions
Governance
Compliance
Master Data Management
Reporting
Data Sources and Supplement/Remediate Data
Slide 20
Global implicationsGlobal implications
• Expanded number of data sources with varying levels of data details
• Management of HCP engagements requires greater coordination a age e t o C e gage e ts equ es g eate coo d at o (e.g., business justification, FMV, spend caps)
• Alignment needed of multiple customer masters with a variety of i IDunique IDs
• Technology systems needed to support global requirements and reportingreporting
• Global roles will need to be defined and responsibilities will need to be shared across organizational boundaries and borders
• Coordinated efforts to successfully achieve global compliance oversight
Slide 21
Q&A ForumQ&A Forum
This publication has been prepared for general guidance on matters of interest only, and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law. PricewaterhouseCoopers LLP, its members, employees and agents do not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.
© 2012 PricewaterhouseCoopers LLP. All rights reserved. "PricewaterhouseCoopers" refers to PricewaterhouseCoopers LLP, a Delaware limited liability partnership, or, as the
t t i th P i t h C l b l t k th b fi f th context requires, the PricewaterhouseCoopers global network or other member firms of the network, each of which is a separate legal entity. This document is for general information purposes only and should not be used as a substitute for consultation with professional advisors.